CASE REPORT
Severe gynaecomastia associated with spironolactone treatment in a patient with decompensated alcoholic liver cirrhosis – Case report
1
1 st Military Teaching Hospital and Polyclinic, Lublin, Poland
2
Department of Internal Medicine, Medical University, Lublin, Poland
3
Cardinal Stefan Wyszyński District Specialist Hospital, Lublin, Poland
Corresponding author
Andrzej Prystupa
Department of Internal Medicine, Medical University, Staszica 16, 20-081 Lublin, Poland
Department of Internal Medicine, Medical University, Staszica 16, 20-081 Lublin, Poland
J Pre Clin Clin Res. 2015;9(1):92-95
KEYWORDS
ABSTRACT
Introduction:
Gynaecomastia is uni- or bilateral breast enlargement in males associated with benign hyperplasia of the glandular, fibrous and adipose tissue resulting from oestrogen-androgen imbalance. Asymptomatic gynaecomastia is a common finding in healthy male adults and does not have to be treated, while symptomatic gynaecomastia might be the symptoma of many pathological conditions and requires meticulous diagnosis and therapeutic management. The commonest causes of gynaecomastia in the Polish population include liver cirrhosis and drugs used to treat its complications. The current study presents the case of severe painless gynaecomastia in a patient with decompensated alcoholic liver cirrhosis, treated with spironolactone because of ascites. Breast enlargement assessed a IIb according to the Simon’s Scale or III according to the Cordova-Moschella classification, developed slowly over the two-year period of low-dose spironolactone therapy The course and dynamics of disease are described and the main mechanisms leading to its development discussed. The importance of effective treatment of patients with severe gynecomastia is emphasized as the disease may result in significant psychosocial problems.
Gynaecomastia is uni- or bilateral breast enlargement in males associated with benign hyperplasia of the glandular, fibrous and adipose tissue resulting from oestrogen-androgen imbalance. Asymptomatic gynaecomastia is a common finding in healthy male adults and does not have to be treated, while symptomatic gynaecomastia might be the symptoma of many pathological conditions and requires meticulous diagnosis and therapeutic management. The commonest causes of gynaecomastia in the Polish population include liver cirrhosis and drugs used to treat its complications. The current study presents the case of severe painless gynaecomastia in a patient with decompensated alcoholic liver cirrhosis, treated with spironolactone because of ascites. Breast enlargement assessed a IIb according to the Simon’s Scale or III according to the Cordova-Moschella classification, developed slowly over the two-year period of low-dose spironolactone therapy The course and dynamics of disease are described and the main mechanisms leading to its development discussed. The importance of effective treatment of patients with severe gynecomastia is emphasized as the disease may result in significant psychosocial problems.
REFERENCES (20)
1.
Johnson RE, Murad MH. Gynecomastia: Pathophysiology, Evaluation, and ManagementMayo Clin Proc. 2009; 84(11): 1010–1015. Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. Am J Med. 1984; 77(4): 633–638.
2.
Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. Am J Med. 1984; 77(4): 633–639.
3.
Trivedi M. Androgen replacement in early alcoholic cirrhosis? Postgrad Med. 2005; 117:32.
5.
Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynaecomastia. Plast Reconstr Surg. 1973; 51: 48.
6.
Alfredo Carlos Simões Dornellas de Barros, Marcelo de Castro Moura Sampaio Gynecomastia: physiopathology, evaluation and treatment. Sao Paulo Med J. 2012; 130(3): 187–197.
7.
Baker HWG, Burger HG, deKretser DM, et al. A study of the endocrine manifestations of liver cirrhosis. Q J Med. 1976; 45(new series):145–178.
8.
Bannister P, Lowosky MS. Ethanol and hypogonadism. Alcohol and Alcoholism 1987; 22(3): 213–217.
9.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10): 709–717.
10.
Satoh T, Fujita KI, Munakata H, et al. Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase. Anal Biochem. 2000; 286(2): 179–186.
11.
Carvajal A, Macias D, Gutie´rrez A, et al. Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System. Drug Saf. 2007; 30(6): 527–531.
12.
Santucci L, Farroni F, Fiorucci S, et al. Gynecomastia during omeprazole therapy. N Engl J Med. 1991; 324(9): 635.
13.
Bellati G, Ideo G. Gynecomastia after spironolactone and potassium cancreonate. Lancet 1986; I: 626.
14.
Overdiek JWPM, Markus FWHM. Spironolactone metabolism and gynecomastia. Lancet 1986; 10:1103.
15.
Dimitriadis G, Papadopoulos V, Mimidis K. Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics. Hepatol Int. 2011; 5: 738–739.
16.
Colombo-Benkmann M, Buse B. Surgical therapy of gynaecomastia and its results. Langenbecks Arch Chir Suppl Kongress. 1998; 11: 1282–1284.
17.
Kasielska A, Antoszewski B. Effect of operative treatment on psychosicial problems of men with gynecomastia. Polski Przegląd Chirurgiczny 2011; 83(11): 614–621.
18.
Loriaux DL, Menard R, Taylor A, Pita JC, Santen R. Spironolactone and endocrine dysfunction. Ann Intern Med. 1976; 85: 630–636.
19.
Coen P, Kulin H, Ballantine T, et al. An aromatase producing sex-cord tumour resulting in prepubertal gynaecomastia. N Engl J Med. 1991; 324(5): 317–322.
20.
Cilotti A, Campassi C, Bagnolesi P, Moretti M, Caramella D, Bartolozzi C. Gynecomastia: diagnostic value of high frequencies ultrasound (10–13 MHz). Breast Dis.1996; 9: 61–69.
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
